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Cardiovascular disease, and particularly coronary heart disease, is an emerging area of concern in the HIV popu-
lation. Since the advent of efficient antiretroviral therapies and the consequent longer patient life span, an in-
creased risk for myocardial infarction has been observed in HIV-infected patients compared with the general
population in Western countries. The pathophysiology of this accelerated atherosclerotic process is complex and
multifactorial. Traditional cardiovascular risk factors—overrepresented in the HIV population—associated with
uncontrolled viral replication and exposure to antiretroviral drugs (per se or through lipid and glucose distur-
bances) could promote acute ischemic events. Thus, despite successful antiviral therapy, numerous studies sug-
gest a role of chronic inflammation, together with immune activation, that could lead to vascular dysfunction
and atherothrombosis. It is time for physicians to prevent coronary heart disease in this high-risk population
through the use of tools employed in the general population. Moreover, the lower median age at which acute
coronary syndromes occur in HIV-infected patients should shift prevention to include patients 45 years of age.
Available cardiovascular risk scores in the general population usually fail to screen young patients at risk for
myocardial infarction. Moreover, the novel vascular risk factors identified in HIV-related atherosclerosis, such as
chronic inflammation, immune activation, and some antiretroviral agents, are not taken into account in the
available risk scores, leading to underestimation of cardiovascular risk in the HIV population. Cardiovascular pre-
vention in HIV-infected patients is a challenge for both cardiologists and physicians involved in HIV care. We re-
quire new tools to assess this higher risk and studies to determine whether intensive primary prevention is
warranted. (J Am Coll Cardiol 2013;61:511–23) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.06.063An association between HIV infection, antiretroviral ther-
apy (ART), and coronary heart disease (CHD) has been
reported in several studies in recent years (1–4). HIV
infection has become a chronic disease in countries in which
effective combination ART (cART) has been available since
the mid-1990s. Over the same period, an increasing number
of reports have been published on the occurrence of acute
coronary syndromes (ACS) in this population, in those age
50 years. This article discusses the current understanding
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accepted June 19, 2012.of the interaction between HIV infection, immune activa-
tion, antiretroviral drugs, conventional risk factors, and
CHD. Several key areas of importance to cardiologists in
the management of patients with HIV infection and CHD
are addressed:
• Is CHD more prevalent, and does it occur prema-
turely, in the HIV population compared to the general
population?
• Does cART affect the risk for CHD?
• Is the pathophysiology of CHD in the HIV-infected
population similar to that in the general population?
• What are the clinical and angiographic presentations
of CHD in the HIV-infected population?
• Is the prognosis of CHD different in HIV-infected patients?
• Can CHD be prevented in patients infected with HIV?
Epidemiology
As a consequence of cART, the spectrum of diseases related
to HIV has shifted in Western countries from opportunistic
AIDS-related diseases toward long-term age-related com-
plications, including cardiometabolic alterations and cancers.
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HIV and CHD February 5, 2013:511–23Recent reports have shown that
cardiovascular deaths accounted
for 6.5% of total deaths in a large
observational cohort of HIV-
infected patients from Europe and
North America, for 8% of deaths
among HIV-infected people in
France, and for 15% of deaths in a
North American HIV outpatient
study (5–7).
Prevalence and incidence of
CHD. Data from 2 observa-
tional studies show that, com-
pared to the general population,
HIV-infected patients have a
higher rate of CHD (defined as
myocardial infarction [MI])
(2,8). In the French Hospital
Database on HIV (FHDH),
compared to the general popula-
tion and irrespective of age class,
the standardized mortality ratio
was 1.5 in HIV-infected men
and women (1.4 for men and 2.7
for women) (2), and in a North
American cohort, the risk ratio was 1.7 (8). In several
cohorts from published studies, the mean age at which MI
occurred in HIV-infected patients was around 48 years, far
less than that reported in the general population. However,
the median age of the HIV population is also far less than
that of the general population, leading to a younger age at
diagnosis of MI. This prematurity, if any, could be due to an
acceleration of atherosclerosis by HIV and/or an earlier
exposure to conventional cardiovascular risk factors.
Impact of cART on CHD. Although it is now clearly
stablished that cART is linked to metabolic disorders, the
ong-term impact of these conditions remains the subject of
iscussion. cART is currently defined as any combination of
antiretroviral drugs, usually 2 nucleoside reverse transcrip-
ase inhibitors (NRTIs) and a protease inhibitor (PI), or a
on-nucleoside reverse transcriptase inhibitor (NNRTI)
nd an integrase inhibitor. The first signs of an increased
isk for CHD possibly related to PIs appeared in 1998, with
he publication of reports of MI occurring in young HIV-
nfected patients treated with PIs and associated with raised
oncentrations of cholesterol (9–12). Thereafter, some
(3,13–20), but not all (21–23), studies have shown a link
between the risk for CHD and exposure to PIs (Table 1).
Although a number of these studies had methodologic
limitations, the 2 most important and recent observational
cohorts (3,20) with a sufficient duration of exposure to PIs
showed that the duration of exposure was associated with an
increased risk for MI. This was the case for cumulative
exposure to any PI (except for saquinavir) (odds ratio: 1.15
per year; 95% confidence interval [CI]: 1.06 to 1.26) in the
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
ART  antiretroviral
therapy
CABG  coronary artery
bypass grafting
cART  combination
antiretroviral therapy
CHD  coronary heart
disease
CYP  cytochrome P450
FHDH  French Hospital
Database on HIV
MI  myocardial infarction
NNRTI  non-nucleoside
reverse transcriptase
inhibitor
NRTI  nucleoside reverse
transcriptase inhibitor
PCI  percutaneous
coronary intervention
PI  protease inhibitorFHDH study (3) and for indinavir or lopinavir/ritonavir(relative risk [RR] [95% CI] per additional year: 1.12 [1.07
to 1.18] and 1.13 [1.05 to 1.21], respectively) but neither for
saquinavir nor nelfinavir in the D:A:D (Data Collection on
Adverse Events of Anti-HIV Drugs) study (20). No con-
clusive data are available on atazanavir or darunavir. After
adjustment for lipid concentrations, the impact of these PIs
(indinavir, lopinavir, ritonavir) remained significant. This
finding may support the direct impact of PIs, independent
of lipid-induced abnormalities, on the risk for MI. More-
over, the rate of MI associated with PI exposure changed
little, regardless of whether the effects of PIs were boosted
with ritonavir (3,20). However, the PI risk–benefits ratio
remains positive, as the increase in life expectancy conferred
by cART far outweighs the associated risk for MI. Law et
al. (24) calculated that the 3-year risk for MI increased from
0.30% (95% CI: 0.20% to 0.38%) in antiretroviral-naive
patients to 1.07% (95% CI: 0.43% to 1.77%) in patients
receiving antiretroviral agents from all 3 classes. In this
publication, the estimated 3-year risk for AIDS or death
was between 6.2% and 11.1% among ART-treated patients
staying on treatment, rising to between 22.5% and 29.4%
when they ceased taking ART. Neither the FHDH nor the
D:A:D study found any significant association between the
development of MI and cumulative exposure to an NNRTI
(efavirenz or nevirapine).
Regarding NRTIs, the D:A:D study (20) found an
association between cumulative and recent exposure to
abacavir and an increased risk for MI (RR [95% CI]: 1.07
[1.00 to 1.14] and 1.70 [1.17 to 2.47], respectively), whereas
the FHDH study (3) did not find any causal relationship
because the observed association with short-term or recent
exposure to abacavir was unstable in sensitivity analyses.
Recent exposure to didanosine was associated with an
increased risk for MI in the D:A:D study (RR: 1.41; 95%
CI: 1.09 to 1.82), but not in the FHDH study. Three
meta-analyses (25–27) and a retrospective study from the
Veterans’ cohort (28) showed no significant association
between abacavir use and MI. In contrast, a retrospective
study nested in the Canadian public health insurance database
showed an increased risk for MI in the HIV population
compared with the general population, and that exposure to
abacavir was associated with an increased risk for MI (29).
These differences can be explained by the presence of con-
founding factors, such as smoking, kidney function, cocaine
and/or intravenous drug use, and potential selection biases.
Therefore, at present it is not possible to draw any conclusions
regarding a causal relationship between treatment with abaca-
vir and the risk for developing MI (30).
Cardiovascular Risk Factors
Patients infected with HIV are at higher calculated risk for
CHD compared with the general population of the same
age (31,32). Typically, compared with age-related controls,
HIV-infected patients exhibit higher rates of conventional
risk factors such as smoking (32), dyslipidemia (31,33),
513JACC Vol. 61, No. 5, 2013 Boccara et al.
February 5, 2013:511–23 HIV and CHDhypertension (34,35), and insulin resistance or diabetes
mellitus (16,33–34,36). Conventional cardiovascular risk
equations do not take into account emerging cardiovascular
risk factors such as inflammation (37,38), immune activa-
tion (39–41), coagulation disorders (42,43), kidney disease
(44), HIV itself (45), and cART that have been associated
with the increased risk of MI or atherosclerosis in HIV-
infected patients. Cocaine use, may increase the risk for
ACS, is relatively common among HIV-infected patients,
particularly in North America, and consumption is increas-
ing in Europe (46). Renal function and albuminuria have
also been strongly associated with the risk for MI in
HIV-infected patients (44). All of these cardiovascular risk
factors are interconnected and synergistic, leading to diffi-
culties in analyzing the specific role of each, particularly the
impact of HIV itself and of cART. Recently, the D:A:D
study group developed a risk-assessment tool tailored to
HIV-infected patients and incorporating exposure to PIs
and NRTIs (47).
Importantly, cardiovascular risk should also be evaluated
in HIV-infected children because vertically infected indi-
viduals have been exposed long-term to both HIV and
cART. A risk for cardiomyopathy has been described in
HIV-infected children exposed to HIV and/or cART from
HIV-infected mothers, and in uninfected children of HIV-
infected mothers exposed to ART (48–50). The presence of
dyslipidemia, chronic inflammation, and subclinical athero-
sclerosis has been reported in HIV-infected children
(51,52). Indeed, a recent study using magnetic resonance
angiography suggested possible early coronary atherosclero-
sis in HIV-infected children (53). Moreover, the risk for
premature atherosclerosis in adulthood among HIV-
infected children requires further investigation to develop
accurate strategies of prevention.
Pathophysiology
The pathophysiology of CHD in HIV-infected patients is
complex, combining both conventional vascular risk factors
and emerging risk factors. The effects of HIV infection in
cART-naive patients and in cART-treated patients should
be considered separately. Many factors associated with the
risk for CAD in HIV-infected patients have been deter-
mined in several studies by association or indirectly and
therefore lead to hypothetic and speculative explanation for
the moment.
HIV infection and risk for CHD in treatment-naive
patients. Recently, Baker and Lundgren (4) reviewed the
potential impact of HIV infection on the cardiovascular
system in untreated HIV-infected patients. They suggested
that HIV infection could promote atherosclerosis through
mechanisms related to immune activation, chronic inflam-
mation, coagulation disorders, and/or lipid disturbances
(Fig. 1). The SMART (Strategies for Management of
Antiretroviral Therapy) study (45) was designed to assess an
HIV treatment strategy of continuous compared with epi-sodic ART guided by CD4 count. That study indirectly
highlighted the role of HIV replication and dysimmunity
after the cessation of ART in the increased risk for MI. In
fact, in the patients on episodic ART, the risk for major
cardiovascular events was greater than in the group on
continuous therapy (hazard ratio [HR] for major cardiovas-
cular, renal, or hepatic disease: 1.7 [95% CI: 1.1 to 2.5; p 
0.009]; HR for fatal or nonfatal cardiovascular disease: 1.6
[95% CI: 1.0 to 2.5; p  0.05]).
Enhanced endothelial injury (Fig. 1) due to adhesion
molecules (54), HIV Tat protein, and related angiogenic
effects (55) has been shown. Direct HIV infection could also
stimulate proliferation of human vascular smooth muscle
cells and therefore promote atherosclerosis (56). HIV infec-
tion could lead to coagulation disorders (a “prothrombic
state”) associated with increased concentrations of D
dimers, fibrinogen, factor VII, von Willebrand and tissue
factors, and abnormal platelet reactivity (43,55). Finally,
HIV alone, independent of cART, is associated with known
atherogenic dyslipidemia associated with increased concen-
trations of triglycerides (impaired lipase activity) and decreased
concentrations of high-density lipoprotein cholesterol corre-
lated with a higher concentration of cytokines (57).
Antiretroviral agents and risk for CHD. In cART-
treated HIV-infected patients, immune activation and low-
grade chronic inflammation may promote atherosclerosis
(Fig. 1). Whether the inflammatory balance and/or immune
activation participates in atherosclerosis acceleration re-
mains debated and speculated (39,58). However, the roles
played by chronic immune activation and inflammation in
HIV pathogenesis have become increasingly apparent and
are associated with pathologies linked with aging and
so-called “inflammaging,” such as bone demineralization,
CHD, cancer, and immune senescence (59). Chronic in-
flammation has been associated with an increased risk for
death (37,60,61). Immune activation can promote athero-
sclerosis and increased arterial stiffness in the absence of
residual viral replication (62–66). Whether the control of
immune activation could decrease accelerated atherosclero-
sis in HIV-infected patients remains to be determined.
Finally, increased intestinal bacterial translocation associ-
ated with immune activation and its impact on atheroscle-
rosis warrants further investigation (67).
Whether cART, and in particular PIs, increases the risk
for CHD has been extensively debated over the past decade
(68,69) (see previous discussion). The impact of cART on
lipid and glucose metabolism via adipocyte dysfunction
leading to a lipodystrophy syndrome (Fig. 1) has been
demonstrated both in vitro and in vivo in HIV-infected
patients (33,36,70). The potential metabolic effects and
proatherogenic effects of each class of antiretroviral agents
are depicted in Table 2 (data should be interpreted with
caution because the metabolic impact of these different
drugs has not been compared directly). These effects vary
from one drug to another, and are associated with other risk
factors such as environmental and genetic factors (71). The
Risk for CHD Among ART-Treated HIV-Infected PatientsTable 1 Risk for CHD Among ART-Treated HIV-Infected Patients
First Author
Year (Ref. #) Design
Events
Studied Period
n
py Coronary Events ART-Exposed Patients; py
Duration of Follow-Up
With ART Results
Friis-Moller et al.
2007 (1)
Specifically designed
cohort; validation of
cases
MI 1999–2005 23,437
94,469 py
345 150,758 py 83 months (median) RR: 1.16 (95% CI: 1.09–1.23) per year of
cART exposure;
RR: 1.16 (95% CI: 1.10–1.23) per year of PI
exposure;
RR: 1.05 (95% CI: 0.98–1.13) per year of
NNRTI exposure
Lang et al.
2010 (3)
Case-control study nested
in database
MI 2000–2006 74,958
298,156 py
289 vs. 884
controls
94% 79 vs. 84 months MI incidence: 1.24/1,000 PY;
OR cumulative exposure to PI (except
saquinavir): 1.53 (95% CI: 1.21–1.94)
per year;
RR recent exposure to abacavir not
significantly increased when taking into
account cocaine and IV drug use (OR: 1.27;
95% CI: 0.60–2.49)
Jütte et al.
1999 (13)
Database on medical
records; no validation
of cases
MI 1990–1998 1,324
1,911 py
8 373
469
10 months (median) Incidence: 2.1/1,000 PY in non–PI-treated
patients vs. 10.6/1,000 PY in PI-treated
patients
Rickerts et al.
2000 (14)
Database on medical
records; validation of
cases
MI 1983–1998 4,993
16,478 py
29 1,572 NR OR: 2.61 (95% CI: 1.19–5.66) cART vs.
no cART
Holmberg et al.
2002 (15)
Database on medical
records; validation of
cases
MI 1993–2002 5,672
17,712 py
21 3,247 49 months (mean) Higher risk for PI vs. non-PI; HR: 6.5
(95% CI: 0.9–47.8)
Friis-Moller et al.
2003 (16)
Specifically designed
cohort; validation of
cases
MI 1999–2002 23,468
36,199 py
126 17,484 py 22 months (median) RR: 1.26 (95% CI 1.12–1.41) per year of cART
exposure
Mary-Krause et al.
2003 (17)
Database on medicals;
validation of cases
MI 1996–1999 34,976 men
88,029 py
60 (49 treated
with PI)
21,906
39,023 py
34 months (median) Higher risk for 30 vs. 18 months of PI
exposure; SMR: 3.6 (95% CI: 1.8–6.2)
D’Arminio Monforte et al.
2004 (18)
Specifically designed
cohort; validation of
cases
CCVE 1999–2002 36,145 py CCVE: 207
MI: 126
NR NR RR: 1.26 (95% CI: 1.14–1.38) per year of
cART exposure
Obel et al.
2007 (19)
Database on medical
records; no validation
of cases
Ischemic CVD 1995–2004 In non-cART period:
9,271 py vs.
1,272,956 py;
in cART period:
13,593 py vs.
1,389,722 py
Before cART
initiation:
14 vs. 1,946;
after cART
initiation:
57 vs. 2,817
13,593 py vs. 1,389,722 py In non-cART period:
1.6 vs. 2.13 yrs;
in cART period: 5.2 vs.
5.9 yrs
After cART initiation, the increased risk
became substantially higher: RR:
2.12 (95% CI: 1.62–2.76);
RR did not further increase in the initial 8 yrs
of cART
Worm et al.
2010 (20)
Specifically designed
cohort; validation of
cases
MI 1999–2008 33,308
178,835 py
580 NR NR MI incidence: 3.2/1,000 PY (95% CI: 3.0–3.5);
RR cumulative exposure to IDV and LPV/RTV:
1.12 (95% CI: 1.07–1.18) and 1.13
(95% CI: 1.05–1.21), respectively;
RR recent exposure to abacavir and
didanosine: 1.70 (95% CI: 1.17–2.47) and
1.41 (95% CI: 1.09–1.82), respectively
Continued on next page
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February 5, 2013:511–23 HIV and CHDeffects of PIs on high-density lipoprotein cholesterol con-
centrations, together with the proper effect of HIV itself on
his lipoprotein, seem to play a crucial role in the increased risk
or CHD in the HIV population, which is much higher than
hat related to the rise in triglyceride concentrations typically
ound in this context (72,73). PI-induced endothelial injury
as been associated with dyslipidemia, oxidative stress, and
enescence (74). In contrast, the AIDS Clinical Trials
roup 5152 study showed that cART improved endothelial
ysfunction in treatment-naive HIV-infected patients after
4 weeks of therapy (75). Therefore, the short-term and
ong-term adverse events with PIs may have a different
mpact on the risk for CHD. Recently, similar molecular
athophysiological mechanisms have been observed in cells
rom patients with the Hutchinson-Gilford syndrome (pro-
eria) and treated with PIs in vitro (74,76). In fact, progeria
s associated with premature aging and early CHD caused
y the accumulation of progerin (truncated prelamin A).
ging of vascular smooth muscle cells is associated with the
ccumulation of prelamin A, leading to premature senes-
ence (76). Importantly, some PIs boosted with ritonavir
nduce in vitro senescence of human fibroblast and endo-
helial cells as the result of prelamin A accumulation (74).
herefore, the authors speculate that premature aging and
arly CHD in HIV-infected patients could be partly caused
y the acquired prelamin A accumulation.
linical Presentation
he spectrum of CHD in HIV-infected patients is similar
o that in non–HIV-infected patients, with various clinical
resentations including silent ischemia, stable angina, and
CS (unstable angina, non–ST-elevation MI and predom-
nant ST-elevation MI). In HIV-infected patients, the
resence of CHD is usually revealed by the occurrence of
CS. In published studies on ACS in HIV-infected pa-
ients (Table 3) (21,77–82), the typical patient is a young
an (50 years of age in90% of cases) with a long known
uration (8 years) of HIV disease (however, this criterion
s not accurate, as the duration of HIV seropositivity does
ot represent the duration of HIV infection, and therefore
he nadir CD4 cell count could be used) who is taking
ART (53% to 96%), generally including a PI (59%); is a
moker (45%); and is dyslipidemic (17% to 58%). In these
tudies, the most frequent presentation is ST-segment
levation MI (29% to 64%), followed by non–ST-segment
levation MI (20% to 48%) and unstable angina (18% to
6%). Men are affected predominantly, as in the general
opulation, representing between 81% and 97% of the
ohorts (21,77–82).
Studies on frequency, causes, and determinants of sudden
eath in HIV-infected patients are lacking. One mechanism
f sudden death could be PI-induced ventricular fibrillation.
n fact, whether HIV PIs induce QT prolongation is being
iscussed, but if this is the case, the impact does not appearto be clinically relevant (83,84).Co T D K B AR
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The coronary angiographic features of CHD in HIV-
infected patients have been reported in a number of studies
that varied in terms of their design (cohort, case control,
cross-sectional) and number of patients enrolled (16 to 103)
(Table 4) (21,77–82,85–87). The extension of CHD is
sually low; between 35% and 56% of patients had 1-vessel
isease; 18% to 28%, 2-vessel disease; and 13% to 76%,
3-vessel disease. The percentage of patients with nonsig-
ificant coronary stenosis (50%), when reported, is low
3% to 14%). Whether the angiographic features of CHD
iffer in the HIV-infected population compared with the
ninfected population is not obvious (80–82,86–87). Only
sue et al. (81) observed that non–HIV-infected patients
ad more extensive disease compared with HIV-infected
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Figure 1 Hypotheses for the Pathophysiology of Atherosclerotic
Antiretroviral therapy and HIV itself could promote coronary heart disease (CHD) a
been associated with the accumulation of visceral fat, epicardial fat, and liver stea
insulin resistance, dyslipidemia, and increased in situ and systemic inflammation)
pose tissue. Residual HIV replication even under potent cART, and reactivation of
and to a degree of immune senescence that could favor atherosclerosis. Chronic
tion in the gut, associated with coagulation disorders. Adipose tissue dysfunction,
dysfunction, leading to atherosclerosis and acute ischemic events. ART  antiretr
HDLc  high-density lipoprotein cholesterol; IL6  interleukin 6; NO  nitrogen ox
activated receptors; RAS  Renin angiotensin system; ROS  reactive oxygen spe
VSMC  vascular smooth muscle cells. Figure illustration by Yves Chrétien, INSERatients (number of diseased vessel 1.9  1.2 vs. 1.3  1; tp  0.007). However, the control group was not matched
or age with the HIV-infected group. In the other studies
80,82,86,87) with the specific angiographic comparison pre-
efined and with age-matched control patients, no differences
ere found (Table 4). The primary method of revasculariza-
ion reported in these publications on ACS is percutaneous
oronary intervention (PCI) (25% to 76%), followed by
oronary artery bypass grafting (CABG) (4% to 18%) and
edical therapy alone (10% to 20%).
rognosis With ACS and
oronary Revascularization
he prognosis of HIV-infected patients during the acute
hase of ACS has been evaluated in a few studies
78 – 80,82). The in-hospital mortality rate varied from 0%
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ith environmental and genetic factors. Adipose tissue and liver dysfunction have
leading to metabolic disturbances (decreased adiponectin and glucose uptake,
HIV and combined antiretroviral therapy (cART) have a deleterious impact on adi-
viruses (e.g., cytomegalovirus [CMV]) could lead to permanent immune activation
ation could persist under cART potentially due to increased microbial transloca-
ne activation, and chronic inflammation could result in vascular and endothelial
herapy; CRP  C-reactive protein; F VII  factor VII; FFA  free fatty acids;
AI-1  plasminogen activator inhibitor type 1; PPAR  peroxisome proliferator-
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February 5, 2013:511–23 HIV and CHDMain Classes of Antiretrovirals and Their Impact on Lipid and Glucose Metabolism and CHDTable 2 Main Classes of Antiretrovirals and Their Impact on Lipid and Glucose Metabolism and CHD
Drug Class Adverse Metabolic Effects Impact on CHD
PI Dyslipidemia*; insulin resistance; variable with different drugs Duration of exposure independently increased risk for MI
Ritonavir Dyslipidemia; insulin resistance This drug is never used alone, but as a pharmacological
booster in association with other PIs
Lopinavir  ritonavir Dyslipidemia; insulin resistance Cumulative exposure independently increased risk for MI
Atazanavir  ritonavir Dyslipidemia; insulin resistance No data available (not enough patients exposed)
Darunavir,  ritonavir Dyslipidemia; insulin resistance No data available (not enough patients exposed)
Indinavir Dyslipidemia; insulin resistance Controversial results
Saquinavir Dyslipidemia; insulin resistance No association with risk for MI
Amprenavir  ritonavir Dyslipidemia; insulin resistance No data available (not enough patients exposed)
Tipranavir  ritonavir Dyslipidemia; insulin resistance No data available (not enough patients exposed)
Nelfinavir Dyslipidemia; insulin resistance No association with risk for MI
NRTI Insulin resistance (stavudine  zidovudine); dyslipidemia
with didanosine and stavudine
Two NRTIs (abacavir and didanosine) have been
associated with an increased risk for MI but
controversial results
NNRTI Dyslipidemia variable with different drugs; efavirenz to a
lesser extent than PIs; nevirapine mild dyslipidemia but
with increased high-density lipoprotein cholesterol
No association with increased risk for MI
Other classes; maraviroc; raltegravir No effects reported No data available (not enough patients exposed)*Dyslipidemia defined as increased total cholesterol, low-density lipoprotein cholesterol, triglycerides and decreased high-density lipoprotein cholesterol.Weak effect.Moderate effect.Important effect.
NRTI  nucleoside reverse transcriptase inhibitors; other abbreviations as in Table 1.Spectrum of Cardiovascular Risk Factors in Several Studies Including HIV-Infected Patients With ACSTable 3 Spectrum of Cardiovascular Risk Factors in Several Studies Including HIV-Infected Patients With ACS
First Author (Ref. #)
HIV Status
Period
Study Design n Age, yrs Type of ACS
Risk Factors, %
cART/PI;
CD4 Cell Count,
Cells/mm3
Nicotine
Use
Cocaine
Use
Premature
Familial CHD Hypertension
Diabetes
Mellitus Dyslipidemia
David et al. (21)
HIV
1999–2000
Retrospective
16 43 (42–66) STEMI 50;
SA 50
81 63 31 63 13 50 69%/100%;
Median: 234;
nadir: 101
Escaut et al. (77)
HIV
2003
17 46 6 STEMI 64;
UA 18;
SA 18
71 0 12 35 24 40 94%/65%;
Mean 272;
Varriale et al. (78)
HIV
1998–2001
Prospective
29 46 10 STEMI 52;
NSTEMI 48
55 10 14 14 10 21 76%/66%;
500: 62%
Ambrose et al. (79)
HIV
1996–2000
Retrospective
51 48 9 STEMI 36;
UA 33;
NSTEMI 31
55 8 45 29 12 48 NA/59%;
Mean: 470
Matetzky et al. (80)
HIV vs. HIV–
1998–2000
24 vs. 48 47 9
vs.
48 7
STEMI 58;
NSTEMI 42;
in the entire
cohort
58 vs. 48* 0 50 vs. 44* 29 vs. 44* 12 vs. 19* 58 vs. 56* 92%/71%;
Mean 318
Hsue et al. (81)
HIV vs. HIV–
1993–2003
Database
68 vs. 68 50 8
vs
61 11
UA 46;
STEMI 29;
NSTEMI 25;
in the entire
cohort
46 vs. 28† NA 24 vs. 16* 36 vs. 41* 9 vs. 28* 17 vs. 28† 53%/92%;
Median: 341;
nadir: 153
Boccara et al. (82)
HIV vs. HIV–
2003–2006
Prospective
103 vs. 195 48 9
vs.
50 9
STEMI 49;
UA 31;
NSTEMI 20;
in the entire
cohort
59 vs. 64* 5 vs. 2* 20 vs. 27* 18 vs. 24* 9 vs. 12* 45 vs. 46* 96%/83%;
Median: 462;
nadir: 123
*p  0.05. †p  0.05.
ACS acute coronary syndromes; NA not available; NSTEMI non–ST-segment elevation myocardial infarction; SA stable angina; STEMI ST elevation myocardial infarction; UA unstable angina;
other abbreviations as in Table 1.
Angiographic and Revascularization Features of CHD in HIV-Infected PatientsTable 4 Angiographic and Revascularization Features of CHD in HIV-Infected Patients
First Author Year (Ref. #)
Population Age, yrs Follow-Up, Months Extent of CHD, % No. of Diseased Vessels Culprit Vessel, % Revascularization, % Clinical Restenosis Rate, %
David 2002 (21)
16 HIV
43 (42–66) No follow-up NR NR NR 68% PCI;
13% CABG;
19% Med
ND
Escaut 2003 (77)
17 HIV
46 6 34 (12–64) 50% 1 VD 2.56 LAD 82%;
LCA 41%;
RCA 35%;
LMD 6%
100% PCI 18% HIV
Varriale 2004 (78)
29 HIV
46 10 ND NR NR NR 35% PCI;
10% CABG
ND
Ambrose 2003 (79)
51 HIV
48 9 ND 47% 1 VD;
22% 2 VD;
20% 3 VD;
11% NSS
NR NR 49% PCI;
18% CABG;
12% Med
ND
Matetzky 2003 (80)
24 HIV, 48 HIV–
47 9 14.7 8 76% 2 VD;
14% NSS
NR NR 71% ATL;
13% CABG
43% HIV
Hsue 2004 (81)
68 HIV, 68 HIV–
50 8 NR NR HIV 1.3 1.0;
HIV– 1.9 1.2*
NR 52% PCI;
11% CABG
52% HIV vs. 14% HIV–*;
with stenting (76%):
50% HIV vs. 18% HIV–‡
Boccara 2011 (82)
103 HIV, 195 HIV–
49 9 12 56% 1 VD;
28% 2 VD;
13% 3 VD;
3% NSS
1.5 0.8
1.5 0.7*
LAD 51%; LCA
14%; RCA 23%;
12% unknown
76% PCI;
4% CABG;
20% Med
9% HIV vs. 7% HIV–;
HR: 1.4 (95% CI: 0.5–3.8)
Mehta 2003 (85)†
129 HIV
42 10 ND 35% 1 VD;
18% 2 VD;
47% 3 VD
NR LAD 62%;
LCA 45%;
RCA 50%;
LMD 6%
25% PCI  CABG ND
Boccara 2006 (86)
50 HIV, 50 HIV–
43 6 20 60% 2D HIV 1.74 0.75;
HIV– 1.62 0.72‡
NR 100% PCI 14% HIV vs. 16% HIV–‡
Ren 2009 (87)
97 HIV, 97 HIV–
53 9 36 NR 2 vs. 2 LAD 42% 100% PCI 18% HIV vs. 13% HIV–;
11% HIV DES vs.
2% HIV– DES
*p  0.05. †From several case reports. ‡p  0.05.
CABG  coronary artery bypass grafting; DES  drug-eluting stent; LAD  left anterior descending; LCA  left circumflex artery; LMD  left main disease; Med  medical therapy alone; ND  not documented; NR  not reported; NSS  not significant stenosis; PCI 
percutaneous coronary intervention; RCA  right coronary artery; VD  vessel disease; other abbreviations as in Table I.
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February 5, 2013:511–23 HIV and CHDreinfarction were found when a control group was included
(80,82). However, when long-term follow-up was per-
formed, HIV-infected patients exhibited a higher rate of
recurrent ischemic events compared with controls, but
long-term cardiovascular and total mortality did not differ
(80,82). In the PACS (Prognosis of Acute Coronary Syn-
drome in HIV-Infected Patients) study (82), recurrent
ACS was more frequent in HIV-infected patients com-
pared to uninfected patients (HR: 6.5; 95% CI: 1.7 to
23.9). After 3 years of follow-up in this cohort, HIV
status and lipid parameters were the only independent
predictors of recurrent ACS (88).
Regarding the prognosis of patients undergoing PCI, the
initial high rate of procedural success appears similar to that
in the general population. Rates of acute and late stent
thrombosis are low (between 1% and 4%) and did not differ
between HIV-infected and uninfected patients in 2 studies
that looked specifically at this endpoint, but these studies
were not powered to detect such a difference (82,87). The
rate of clinical restenosis has been evaluated in a few studies
(77,80–82,87), varying from 9% to 52%, and did not differ
from that in controls in the stenting group (81,82,87). Ren
et al. (87)—in a single-center study in California–compared
the rate of clinical restenosis between HIV-infected and
uninfected patients undergoing PCI with bare-metal stents
or drug-eluting stents. The investigators found that drug-
eluting stents decreased the rate of major adverse cardiac
events (MACE) in both groups by around 60% compared to
the HIV-uninfected patients who received bare-metal stents
after a 3-year follow-up, without an increased rate of stent
thrombosis. They concluded that drug-eluting stents are as
safe and as efficacious in the HIV-infected population as in
the general population. In addition, in both the study by
Ren et al. (87) and a study by the authors (82), HIV status
did not predict target lesion revascularization (odds ratio
[95% CI]: 1.3 [0.6 to 3.0]; HR [95% CI]: 1.4 [0.5 to 3.8],
respectively) or MACE (odds ratio [95% CI]: 1.1 [0.6 to
2.0]; HR [95% CI]: 1.4 [0.6 to 3.0], respectively). Recently,
a meta-analysis showed that HIV-infected patients with
ACS had a significant long-term risk for recurrent coronary
revascularization and MI (89).
Concerning CABG, only a few studies (90–93) have
Clinical Studies Published on CABG Surgery in HIV-Infected PatientTable 5 Clinical Studies Published on CABG Surgery in HIV-Infe
Study/First Author (Ref. #), Period, Mean Age
Patients Undergoing
CABG
Trachiotis (90), 1994–2000, 41 yrs 27 HIV
Filsousfi (91), 1998–2004, 47 yrs 7 HIV
Jimenez-Exposito (92), 1997–2004, 35 yrs 7 HIV, 21 HIV–
Boccara (93), 1997–2005, 47 yrs 27 HIV, 54 HIV-
Modified from Boccara et al. (93).
CABG  coronary artery bypass grafting.included HIV-infected patients (Table 5). These studiesshowed that the immediate and postoperative periods after
CABG are uneventful and do not differ from those in
non–HIV-infected patients. At long-term follow-up, there
was no difference in rate of cardiovascular death. CABG
had no immunosuppressive effects and did not worsen the
prognosis of patients with HIV disease. Regarding heart
transplantation in HIV-infected patients with severe left
ventricular dysfunction, few data are available (94,95), but
HIV itself is not a contraindication, but the authors recom-
mend case-by-case discussions between HIV physicians and
cardiologists.
Prevention and Treatment
Cardiovascular risk stratification in HIV-infected patients
needs to be evaluated before starting and during treatment
with cART. Reducing risk factors should become routine in
the care of HIV-infected patients, who now live longer.
Intervention studies aimed at reducing cardiovascular risk in
HIV-infected patients are now warranted (e.g., smoking
cessation, increased physical activity, use of lipid-lowering
drugs and aspirin).
Guidelines on cardiovascular risk reduction in HIV-
infected patients have been published and generally follow
those for the general population (96–98). It is important to
highlight the treatment of atherogenic dyslipidemia fre-
quently found in HIV-infected patients taking cART.
Serum concentrations of lipids, particularly triglycerides,
should be evaluated in the fasting patient before cART is
started, at 3 to 6 months after initiation, and then yearly in
the absence of abnormalities. National Cholesterol Educa-
tion Program III guidelines should be applied to HIV-
infected patients, as suggested by other guidelines for the
management of dyslipidemia in HIV-infected patients (96–99).
Lipid-lowering therapy should be prescribed with caution in
HIV-infected patients because of the potentially severe
interaction between statins and fibrates, as well as PIs
(Table 6). Several statins are metabolized via the cyto-
chrome P450 (CYP) 3A4 pathway. PIs and ritonavir mainly
inhibit CYP and could increase the toxicity of some statins
(Table 6). NNRTIs (e.g., efavirenz) are inducers of CYP
and could reduce statin efficacy. In the HIV-infected patient
Patients
ital
th
Pre- vs. Post-Operative
Immune Status Long-Term Survival
No change 81% Event-free at 36 months;
no late death
No change No late death at 47 months
No change 100% Event-free at 30 months;
no difference vs. HIV–
15% decrease in CD4 cell count,
without clinical complications
54% Event-free at 41 monthsscted
Hosp
Dea
0
0
0
0taking a PI, if a statin is prescribed (e.g., for primary or
QV  s
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HIV and CHD February 5, 2013:511–23secondary prevention in the high-risk patient), the prefera-
ble choice is pravastatin, fluvastatin, low-dose atorvastatin,
or low-dose rosuvastatin, as these statins have a low risk for
interaction with PIs (99–101). Pitavastatin—a new statin
not metabolized by the CYP 3A4 isozyme and primarily
excreted unchanged in the bile with little renal elimina-
tion—has not been evaluated in this context but could
present a therapeutic option; this statin has not, however,
shown any clinical benefit in randomized trials (102).
Whether a PI should be switched to an NNRTI or to a new
drug such as integrase or chemokine (C-C motif) receptor 5
(CCR5) inhibitors when dyslipidemia is present, to avoid
adjunctive therapy with a statin, is debatable. In fact,
physicians treating HIV-infected patients have several ther-
apeutic options in this context: to continue PI therapy and
add a statin or to switch the PI to an NNRTI or a novel
drug such as an integrase inhibitor. No trials comparing the
2 strategies in terms of cardiovascular prevention have been
performed. The impact on lipids of switching from first-
generation NRTIs to second-generation NRTIs is low (as
they are less proatherogenic), and the associated beneficial
impact on CHD is unknown. Fibrates should be prescribed
when the triglyceride concentration is above 500 mg/dL
(96–98). In this case, the measurements of non–high-
density lipoprotein cholesterol, apolipoprotein B, or both
may be useful because low-density lipoprotein cholesterol
measurement may underestimate the true CHD risk, espe-
cially in lipodystrophic patients. Ezetimibe may be useful
and well tolerated in achieving the low-density lipoprotein
goal in association with a statin (103), as HIV-infected
patients are susceptible to muscular pain before statin
prescription. However, no clinical benefit of ezetimibe has
been shown in the general population except for patients
with chronic kidney disease in primary prevention (104).
The risk– benefits ratio of treating HIV-infected patients
Interactions Between Lipid-Lowering Drugs and ARTTable 6 Interactions Between Lipid-Lowering Drugs and ART
Drug Cytochrome P450* Interactions With O
Rosuvastatin No or weak P450 interactions Increased AUC with LPV
decreased with NNRTI (
Atorvastatin 3A4 Increased AUC with RTV
decreased with NNRTI (
Pravastatin No P450 interactions AUC decreased with RT
and increased with DRV
decreased with NNRTI (
Fluvastatin 2C9 NNRTI (etravirine) could
Simvastatin 3A4 32-fold increase in AUC
decreased with NNRTI (
Lovastatin 3A4 Not tested
Pitavastatin No P450 interactions Not tested
Bezafibrate No P450 interactions Not tested
Fenofibrate No P450 interactions Not tested
Gemfibrozil Interaction with statins Not tested
Ezetimibe No P450 interactions Not tested
*Involved in lipid lowering drug metabolism.
ATV  atazanavir; AUC  area under the plasma concentration–time curve; DRV  darunavir; Swith dyslipidemia is unknown. Male patients age 45years and female patients 55 years with hypertension
and/or diabetes and/or familial premature CHD are
candidates for lipid-lowering therapy. In secondary pre-
vention, whether PI therapy should be discontinued after
an ACS and cART switched, if virologically possible, to
a drug class with a better “atherogenic profile,” needs
further investigation. Finally, statins as potent lipid-
lowering drugs and major agents in primary and second-
ary cardiovascular prevention, along with their properties
to reverse PI-related senescence of cells and accumulation
of prelamin A in vitro (74) and inflammation in vivo
(105), need to be tested in a large study of primary
prevention in HIV-infected patients.
Regarding hypertension, blockers of the renin angioten-
sin system should be the first therapy because of their
protective effects on the vasculature, on glucose metabolism
and kidney function (44,70).
The prescription of antiplatelet drugs such as aspirin,
clopidogrel, prasugrel, and ticagrelor should follow the
guidelines for the general population (106). In primary
prevention, aspirin should be given if the level of CHD risk
is high and in the absence of contraindications (107).
Recently, questions have been raised about platelet function
and activity in HIV-infected patients (42,108). A potential
interaction between the most commonly prescribed PI
(ritonavir) and prasugrel has been found recently (by
decreasing its activity) in vitro (109). Ticagrelor is me-
tabolized by CYP 3A4/5 and should not be prescribed in
HIV-infected patients undergoing PI therapy, particu-
larly ritonavir (a potent inhibitor of this CYP isozyme)
(110). Studies on antiplatelet “resistance” in HIV-
infected patients need to be performed urgently. How-
ever, the rate of stent thrombosis after PCI does not
appear to be higher in the HIV population than in the
ntiretrovirals Recommendation
nd ATV-RTV;
nz)
Recommended at 5–10 mg daily
nz)
Recommended at 10 mg daily
nz)
Recommended at 20–40 mg daily
se plasma level Recommended at 40 mg daily
TV-SQV;
nz)
Possible high toxicity with PI;
not recommended
Possible high toxicity with PI; not recommended
No recommendations at present
Recommended at 400 mg daily
Recommended at 200 mg daily
Recommended at 900–1,200 mg daily
Recommended with statin, or alone if statin not tolerated
aquinavir; other abbreviations as in Table 1.ther A
-RTV a
efavire
-SQV;
efavire
V-SQV
;
efavire
increa
with R
efavirenon–HIV-infected patients (82,87).
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February 5, 2013:511–23 HIV and CHDConclusions
With their longer life expectancy—due to the use of
cART—HIV-infected patients are increasingly at risk for
CHD. Available data suggest the presence of an accelerated
process of coronary atherosclerosis in this population due to
multiple factors, including a higher prevalence (compared
with non–HIV-infected patients) of conventional risk fac-
tors, emerging risk factors (chronic inflammation, immune
activation, and senescence related to HIV infection itself),
and the role of cART. Evaluating new strategies to prevent
CHD in HIV-infected patients is a major concern. Opti-
mizing cART for each individual to reduce the risk for
CHD is warranted. Understanding the pathophysiology of
the atherosclerotic aging process in this population requires
further investigation. Management of CHD should follow
the same recommendations as those for the general popu-
lation, with caution exercised due to the potential for
drug–drug interactions, particularly with statins and PIs.
Whether aggressive primary and secondary prevention of
CHD and of substantial ischemic events should be recom-
mended in the HIV population needs further evidence.
Acknowledgment
Sophie Rushton-Smith, PhD, provided editorial support on
the final version of this manuscript; her support was funded
by the authors.
Reprint requests and correspondence: Dr. Ariel Cohen or Dr.
Franck Boccara, Department of Cardiology, Saint Antoine Uni-
versity Hospital, 184 rue du Faubourg St Antoine, 75571 Paris,
Cedex 12, France. E-mail: ariel.cohen@sat.aphp.fr or franck.
boccara@sat.aphp.fr.
REFERENCES
1. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs
and the risk of myocardial infarction. N Engl J Med 2007;356:1723–35.
2. Lang S, Mary-Krause M, Cotte L, et al. Increased risk of myocardial
infarction in HIV-infected patients in France, relative to the general
population. AIDS 2010;24:1228–30.
3. Lang S, Mary-Krause M, Cotte L, et al. Impact of individual
antiretroviral drugs on the risk of myocardial infarction in human
immunodeficiency virus-infected patients: a case-control study nested
within the French Hospital Database on HIV ANRS cohort CO4.
Arch Intern Med 2010;170:1228–38.
4. Baker JV, Lundgren JD. Cardiovascular implications from untreated
human immunodeficiency virus infection. Eur Heart J 2011;32:945–51.
5. Lewden C, May T, Rosenthal E, et al. Changes in causes of death
among adults infected by HIV between 2000 and 2005: The
”Mortalite 2000 and 2005” surveys (ANRS EN19 and Mortavic). J
Acquir Immune Defic Syndr 2008;48:590–8.
6. Causes of death in HIV-1-infected patients treated with antiretro-
viral therapy, 1996-2006: collaborative analysis of 13 HIV cohort
studies. Clin Infect Dis 2010;50:1387–96.
7. Palella FJ, Jr., Baker RK, Moorman AC, et al. Mortality in the highly
active antiretroviral therapy era: changing causes of death and disease
in the HIV outpatient study. J Acquir Immune Defic Syndr 2006;
43:27–34.
8. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute
myocardial infarction rates and cardiovascular risk factors among
patients with human immunodeficiency virus disease. J Clin Endo-
crinol Metab 2007;92:2506–12.9. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary
artery disease with protease inhibitors. Lancet 1998;351:1328.
10. Behrens G, Schmidt H, Meyer D, Stoll M, Schmidt RE. Vascular
complications associated with use of HIV protease inhibitors. Lancet
1998;351:1958.
11. Gallet B, Pulik M, Genet P, Chedin P, Hiltgen M. Vascular
complications associated with use of HIV protease inhibitors. Lancet
1998;351:1958–9.
12. Vittecoq D, Escaut L, Monsuez JJ. Vascular complications associated
with use of HIV protease inhibitors. Lancet 1998;351:1959.
13. Jutte A, Schwenk A, Franzen C, et al. Increasing morbidity from
myocardial infarction during HIV protease inhibitor treatment?
AIDS 1999;13:1796–7.
14. Rickerts V, Brodt H, Staszewski S, Stille W. Incidence of myocardial
infarctions in HIV-infected patients between 1983 and 1998: the
Frankfurt HIV-cohort study. Eur J Med Res 2000;5:329–33.
15. Holmberg SD, Moorman AC, Williamson JM, et al. Protease
inhibitors and cardiovascular outcomes in patients with HIV-1.
Lancet 2002;360:1747–8.
16. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretro-
viral therapy and the risk of myocardial infarction. N Engl J Med
2003;349:1993–2003.
17. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D.
Increased risk of myocardial infarction with duration of protease
inhibitor therapy in HIV-infected men. AIDS 2003;17:2479–86.
18. d’Arminio A, Sabin CA, Phillips AN, et al. Cardio- and cerebrovas-
cular events in HIV-infected persons. AIDS 2004;18:1811–7.
19. Obel N, Thomsen HF, Kronborg G, et al. Ischemic heart disease in
HIV-infected and HIV-uninfected individuals: a population-based
cohort study. Clin Infect Dis 2007;44:1625–31.
20. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction
in patients with HIV infection exposed to specific individual antiret-
roviral drugs from the 3 major drug classes: the data collection on
adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis
2010;201:318–30.
21. David MH, Hornung R, Fichtenbaum CJ. Ischemic cardiovascular
disease in persons with human immunodeficiency virus infection.
Clin Infect Dis 2002;34:98–102.
22. Klein D, Hurley LB, Quesenberry CP Jr., Sidney S. Do protease
inhibitors increase the risk for coronary heart disease in patients with
HIV-1 infection? J Acquir Immune Defic Syndr 2002;30:471–7.
23. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardio-
vascular and cerebrovascular events in patients treated for human
immunodeficiency virus infection. N Engl J Med 2003;348:702–10.
24. Law M, Friis-Moller N, Weber R, et al. Modelling the 3-year risk of
myocardial infarction among participants in the Data Collection on
Adverse Events of Anti-HIV Drugs (DAD) study. HIV Med
2003;4:1–10.
25. Ribaudo HJ, Benson CA, Zheng Y, et al. No risk of myocardial
infarction associated with initial antiretroviral treatment containing
abacavir: short and long-term results from ACTG A5001/ALLRT.
Clin Infect Dis 2011;52:929–40.
26. Cruciani M, Zanichelli V, Serpelloni G, et al. ABACAVIR use and
cardiovascular disease events: a meta-analysis of published and
unpublished data. AIDS 2011;25:1993–2004.
27. Ding X, Andraca-Carrera E, Cooper C, et al. No association of
abacavir use with myocardial infarction: findings of an FDA meta-
analysis. J Acquir Immune Defic Syndr 2012;61:441–7.
28. Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P.
Abacavir use and risk of acute myocardial infarction and cerebrovas-
cular events in the highly active antiretroviral therapy era. Clin Infect
Dis 2011;53:84–91.
29. Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL. Associa-
tion between HIV infection, antiretroviral therapy, and risk of acute
myocardial infarction: a cohort and nested case-control study using
Quebec’s public health insurance database. J Acquir Immune Defic
Syndr 2011;57:245–53.
30. Costagliola D, Lang S, Mary-Krause M, Boccara F. Abacavir and
cardiovascular risk: reviewing the evidence. Curr HIV/AIDS Rep
2010;7:127–33.
31. Saves M, Chene G, Ducimetiere P, et al. Risk factors for coronary
heart disease in patients treated for human immunodeficiency virus
infection compared with the general population. Clin Infect Dis
2003;37:292–8.
522 Boccara et al. JACC Vol. 61, No. 5, 2013
HIV and CHD February 5, 2013:511–2332. Kaplan RC, Kingsley LA, Sharrett AR, et al. Ten-year predicted
coronary heart disease risk in HIV-infected men and women. Clin
Infect Dis 2007;45:1074–81.
33. Grinspoon SK. Metabolic syndrome and cardiovascular disease in
patients with human immunodeficiency virus. Am J Med 2005;118
Suppl 2:23S–8S.
34. Gazzaruso C, Bruno R, Garzaniti A, et al. Hypertension among HIV
patients: prevalence and relationships to insulin resistance and met-
abolic syndrome. J Hypertens 2003;21:1377–82.
35. Baekken M, Os I, Sandvik L, Oektedalen O. Hypertension in an
urban HIV-positive population compared with the general popula-
tion: influence of combination antiretroviral therapy. J Hypertens
2008;26:2126–33.
36. Capeau J. From lipodystrophy and insulin resistance to metabolic
syndrome: HIV infection, treatment and aging. Curr Opin HIV
AIDS 2007;2:247–52.
37. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive
protein and HIV infection with acute myocardial infarction. J Acquir
Immune Defic Syndr 2009;51:268–73.
38. Mangili A, Polak JF, Quach LA, Gerrior J, Wanke CA. Markers of
atherosclerosis and inflammation and mortality in patients with HIV
infection. Atherosclerosis 2011;214:468–73.
39. Coll B, Parra S, Alonso-Villaverde C, et al. The role of immunity and
inflammation in the progression of atherosclerosis in patients with
HIV infection. Stroke 2007;38:2477–84.
40. Kaplan RC, Kingsley LA, Gange SJ, et al. Low CD4 T-cell count
as a major atherosclerosis risk factor in HIV-infected women and
men. AIDS 2008;22:1615–24.
41. Lang S, Mary-Krause M, Simon A, et al. HIV replication and
immune status are independent predictors of the risk of myocardial
infarction in HIV-infected individuals. Clin Infect Dis 2012;55:
600–7.
42. Satchell CS, Cotter AG, O’Connor EF, et al. Platelet function and
HIV: a case-control study. AIDS 2010;24:649–57.
43. Baker JV, Neuhaus J, Duprez D, et al. Changes in inflammatory and
coagulation biomarkers: a randomized comparison of immediate
versus deferred antiretroviral therapy in patients with HIV infection.
J Acquir Immune Defic Syndr 2011;56:36–43.
44. Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak
MG. Association between kidney function and albuminuria with
cardiovascular events in HIV-infected persons. Circulation 2010;121:
651–8.
45. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4 count-guided
interruption of antiretroviral treatment. N Engl J Med 2006;355:
2283–96.
46. Carrillo X, Curos A, Muga R, Serra J, Sanvisens A, Bayes-Genis A.
Acute coronary syndrome and cocaine use: 8-year prevalence and
inhospital outcomes. Eur Heart J 2011;32:1244–50.
47. Friis-Moller N, Thiebaut R, Reiss P, et al. Predicting the risk of
cardiovascular disease in HIV-infected patients: the data collection
on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev
Rehabil 2010;17:491–501.
48. Lipshultz SE, Easley KA, Orav EJ, et al. Cardiovascular status of
infants and children of women infected with HIV-1 (P(2)C(2) HIV):
a cohort study. Lancet 2002;360:368–73.
49. Lipshultz SE, Shearer WT, Thompson B, et al. Cardiac effects of
antiretroviral therapy in HIV-negative infants born to HIV-positive
mothers: NHLBI CHAART-1 (National Heart, Lung, and Blood
Institute Cardiovascular Status of HAART Therapy in HIV-
Exposed Infants and Children cohort study). J Am Coll Cardiol
2011;57:76–85.
50. Fisher SD, Easley KA, Orav EJ, et al. Mild dilated cardiomyopathy
and increased left ventricular mass predict mortality: the prospective
P2C2 HIV Multicenter Study. Am Heart J 2005;150:439–47.
51. Ross AC, O’Riordan MA, Storer N, Dogra V, McComsey GA.
Heightened inflammation is linked to carotid intima-media thickness
and endothelial activation in HIV-infected children. Atherosclerosis
2010;211:492–8.
52. Chantry CJ, Hughes MD, Alvero C, et al. Lipid and glucose
alterations in HIV-infected children beginning or changing antiret-
roviral therapy. Pediatrics 2008;122:e129–38.
53. Mikhail IJ, Purdy JB, Dimock DS, et al. High rate of coronary artery
abnormalities in adolescents and young adults infected with humanimmunodeficiency virus early in life. Pediatr Infect Dis J 2011;
30:710–2.
54. de Gaetano Donati K, Rabagliati R, Iacoviello L, Cauda R. HIV
infection, HAART, and endothelial adhesion molecules: current
perspectives. Lancet Infect Dis 2004;4:213–22.
55. Gresele P, Falcinelli E, Sebastiano M, Baldelli F. Endothelial and
platelet function alterations in HIV-infected patients. Thromb Res
2012;129:301–8.
56. Eugenin EA, Morgello S, Klotman ME, et al. Human immunode-
ficiency virus (HIV) infects human arterial smooth muscle cells in
vivo and in vitro: implications for the pathogenesis of HIV-mediated
vascular disease. Am J Pathol 2008;172:1100–11.
57. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold
KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in
human immunodeficiency virus infection and the acquired immuno-
deficiency syndrome. J Clin Endocrinol Metab 1992;74:1045–52.
58. Fisher SD, Miller TL, Lipshultz SE. Impact of HIV and highly
active antiretroviral therapy on leukocyte adhesion molecules, arterial
inflammation, dyslipidemia, and atherosclerosis. Atherosclerosis
2006;185:1–11.
59. Appay V, Sauce D. Immune activation and inflammation in HIV-1
infection: causes and consequences. J Pathol 2008;214:231–41.
60. Tien PC, Choi AI, Zolopa AR, et al. Inflammation and mortality in
HIV-infected adults: analysis of the FRAM study cohort. J Acquir
Immune Defic Syndr 2010;55:316–22.
61. Neuhaus J, Jacobs DR Jr., Baker JV, et al. Markers of inflammation,
coagulation, and renal function are elevated in adults with HIV
infection. J Infect Dis 2010;201:1788–95.
62. Hsue PY, Hunt PW, Sinclair E, et al. Increased carotid intima-media
thickness in HIV patients is associated with increased
cytomegalovirus-specific T-cell responses. AIDS 2006;20:2275–83.
63. Ross AC, Rizk N, O’Riordan MA, et al. Relationship between
inflammatory markers, endothelial activation markers, and carotid
intima-media thickness in HIV-infected patients receiving antiretro-
viral therapy. Clin Infect Dis 2009;49:1119–27.
64. Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication,
antiretroviral therapy, and immunodeficiency in HIV-associated
atherosclerosis. AIDS 2009;23:1059–67.
65. Crowe SM, Westhorpe CL, Mukhamedova N, Jaworowski A,
Sviridov D, Bukrinsky M. The macrophage: the intersection between
HIV infection and atherosclerosis. J Leukoc Biol 2010;87:589–98.
66. Kaplan RC, Sinclair E, Landay AL, et al. T cell activation and
senescence predict subclinical carotid artery disease in HIV-infected
women. J Infect Dis 2011;203:452–63.
67. Redd AD, Gray RH, Quinn TC. Is microbial translocation a cause or
consequence of HIV disease progression? J Infect Dis 2011;203:
744–5; author reply 6.
68. Currier JS, Lundgren JD, Carr A, et al. Epidemiological evidence for
cardiovascular disease in HIV-infected patients and relationship to
highly active antiretroviral therapy. Circulation 2008;118:e29–35.
69. Boccara F. Cardiovascular complications and atherosclerotic mani-
festations in the HIV-infected population: type, incidence and
associated risk factors. AIDS 2008;22 Suppl 3:S19–26.
70. Boccara F, Auclair M, Cohen A, et al. HIV protease inhibitors
activate the adipocyte renin angiotensin system. Antivir Ther 2010;
15:363–75.
71. Caron-Debarle M, Boccara F, Lagathu C, et al. Adipose tissue as a
target of HIV-1 antiretroviral drugs. potential consequences on
metabolic regulations. Curr Pharm Des. 2010;16:3352–60.
72. Rose H, Hoy J, Woolley I, et al. HIV infection and high density
lipoprotein metabolism. Atherosclerosis 2008;199:79–86.
73. Worm SW, Kamara DA, Reiss P, et al. Elevated triglycerides and
risk of MI in HIV-positive persons, the D:A:D study. AIDS
2011;25:1497–504.
74. Lefevre C, Auclair M, Boccara F, et al. Premature senescence of
vascular cells is induced by HIV protease inhibitors. Implication of
prelamin a and reversion by statin. Arterioscler Thromb Vasc Biol
2010;30:2611–20.
75. Torriani FJ, Komarow L, Parker RA, et al. Endothelial function in
human immunodeficiency virus-infected antiretroviral-naive subjects
before and after starting potent antiretroviral therapy: the ACTG
(AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol
2008;52:569–76.
11
1
1
1
1
1
1
1
1
1
523JACC Vol. 61, No. 5, 2013 Boccara et al.
February 5, 2013:511–23 HIV and CHD76. Ragnauth CD, Warren DT, Liu Y, et al. Prelamin A acts to
accelerate smooth muscle cell senescence and is a novel biomarker of
human vascular aging. Circulation 2010;121:2200–10.
77. Escaut L, Monsuez JJ, Chironi G, et al. Coronary artery disease in
HIV infected patients. Intensive Care Med 2003;29:969–73.
78. Varriale P, Saravi G, Hernandez E, Carbon F. Acute myocardial
infarction in patients infected with human immunodeficiency virus.
Am Heart J 2004;147:55–9.
79. Ambrose JA, Gould RB, Kurian DC, et al. Frequency of and
outcome of acute coronary syndromes in patients with human
immunodeficiency virus infection. Am J Cardiol 2003;92:301–3.
80. Matetzky S, Domingo M, Kar S, et al. Acute myocardial infarction
in human immunodeficiency virus-infected patients. Arch Intern
Med 2003;163:457–60.
81. Hsue PY, Giri K, Erickson S, et al. Clinical features of acute coronary
syndromes in patients with human immunodeficiency virus infection.
Circulation 2004;109:316–9.
82. Boccara F, Mary-Krause M, Teiger E, et al. Acute coronary syn-
drome in human immunodeficiency virus-infected patients: charac-
teristics and 1 year prognosis. Eur Heart J 2011;32:41–50.
83. Charbit B, Rosier A, Bollens D, et al. Relationship between HIV
protease inhibitors and QTc interval duration in HIV-infected patients:
a cross-sectional study. Br J Clin Pharmacol 2009;67:76–82.
84. Singh M, Arora R, Jawad E. HIV protease inhibitors induced
prolongation of the QT Interval: electrophysiology and clinical
implications. Am J Ther 2010;17:e193–201.
85. Mehta NJ, Khan IA. HIV-associated coronary artery disease. Angi-
ology 2003;54:269–75.
86. Boccara F, Teiger E, Cohen A, et al. Percutaneous coronary
intervention in HIV infected patients: immediate results and long
term prognosis. Heart 2006;92:543–4.
87. Ren X, Trilesskaya M, Kwan DM, Nguyen K, Shaw RE, Hui PY.
Comparison of outcomes using bare metal versus drug-eluting stents
in coronary artery disease patients with and without human immu-
nodeficiency virus infection. Am J Cardiol 2009;104:216–22.
88. Boccara F, Mary-Krause M, Teiger E, et al. HIV-infected patients
have an increased risk of recurrent ischemic events as compared to
the general population after an acute coronary syndrome. Pre-
sented at: American Heart Association Congress, November 2011,
Orlando, FL.
89. D’Ascenzo F, Cerrato E, Biondi-Zoccai G, et al. Acute coronary
syndromes in human immunodeficiency virus patients: a meta-
analysis investigating adverse event rates and the role of antiretroviral
therapy. Eur Heart J 2012;33:875–80.
90. Trachiotis GD, Alexander EP, Benator D, Gharagozloo F. Cardiac
surgery in patients infected with the human immunodeficiency virus.
Ann Thorac Surg 2003;76:1114–8; discussion 8.
91. Filsoufi F, Salzberg SP, Harbou KT, Neibart E, Adams DH.
Excellent outcomes of cardiac surgery in patients infected with HIV
in the current era. Clin Infect Dis 2006;43:532–6.
92. Jimenez-Exposito MJ, Mestres CA, Claramonte X, et al. Mortality
and morbidity in HIV-infected patients undergoing coronary artery
bypass surgery: a case control study [in Spanish]. Rev Esp Cardiol
2006;59:276–9.
93. Boccara F, Cohen A, Di Angelantonio E, et al. Coronary artery
bypass graft in HIV-infected patients: a multicenter case control
study. Curr HIV Res 2008;6:59–64.
94. Calabrese LH, Albrecht M, Young J, et al. Successful cardiac
transplantation in an HIV-1-infected patient with advanced disease.
N Engl J Med 2003;348:2323–8.
95. Boignard A, Blanc M, Chavanon O. High-urgency priority heart
transplantation in HIV-positive patients on life support: breaking
barriers? J Heart Lung Transplant 2011;30:968–9.96. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation
and management of dyslipidemia in human immunodeficiency virus(HIV)-infected adults receiving antiretroviral therapy: reco-
mmendations of the HIV Medical Association of the Infectious
Disease Society of America and the Adult AIDS Clinical Trials
Group. Clin Infect Dis 2003;37:613–27.
97. Grinspoon SK, Grunfeld C, Kotler DP, et al. State of the science
conference: Initiative to decrease cardiovascular risk and increase
quality of care for patients living with HIV/AIDS: executive sum-
mary. Circulation 2008;118:198–210.
98. Lundgren JD, Battegay M, Behrens G, et al. European AIDS
Clinical Society (EACS) guidelines on the prevention and manage-
ment of metabolic diseases in HIV. HIV Med 2008;9:72–81.
99. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines
for the management of dyslipidaemias: the Task Force for the
management of dyslipidaemias of the European Society of Cardiol-
ogy (ESC) and the European Atherosclerosis Society (EAS). Eur
Heart J 2011;32:1769–818.
00. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic
interactions between protease inhibitors and statins in HIV serone-
gative volunteers: ACTG Study A5047. AIDS 2002;16:569–77.
01. Aslangul E, Assoumou L, Bittar R, et al. Rosuvastatin versus
pravastatin in dyslipidemic HIV-1-infected patients receiving pro-
tease inhibitors: a randomized trial. AIDS 2010;24:77–83.
02. Wensel TM, Waldrop BA, Wensel B. Pitavastatin: a new HMG-
CoA reductase inhibitor. Ann Pharmacother 2010;44:507–14.
03. Chow D, Chen H, Glesby MJ, et al. Short-term ezetimibe is well
tolerated and effective in combination with statin therapy to treat
elevated LDL cholesterol in HIV-infected patients. AIDS 2009;23:
2133–41.
04. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL
cholesterol with simvastatin plus ezetimibe in patients with chronic
kidney disease (Study of Heart and Renal Protection): a randomised
placebo-controlled trial. Lancet 2011;377:2181–92.
05. Aslangul E, Fellahi S, Assoumou LK, Bastard JP, Capeau J,
Costagliola D. High-sensitivity C-reactive protein levels fall during
statin therapy in HIV-infected patients receiving ritonavir-boosted
protease inhibitors. AIDS 2011;25:1128–31.
06. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA
focused update of the guidelines for the management of patients with
unstable angina/non-ST-elevation myocardial infarction (updating
the 2007 guideline): a report of the American College of Cardiology
Foundation/American Heart Association Task Force on Practice
Guidelines Developed in Collaboration With the American College
of Emergency Physicians, Society for Cardiovascular Angiography
and Interventions, and Society of Thoracic Surgeons. J Am Coll
Cardiol 2011;57:1920–59.
07. Wolff T, Miller T, Ko S. Aspirin for the primary prevention of
cardiovascular events: an update of the evidence for the U.S. Preven-
tive Services Task Force. Ann Intern Med 2009;150:405–10.
08. Corrales-Medina VF, Simkins J, Chirinos JA, et al. Increased levels
of platelet microparticles in HIV-infected patients with good re-
sponse to highly active antiretroviral therapy. J Acquir Immune Defic
Syndr 2010;54:217–8.
09. Daali Y, Ancrenaz V, Bosilkovska M, Dayer P, Desmeules J.
Ritonavir inhibits the two main prasugrel bioactivation pathways in
vitro: a potential drug-drug interaction in HIV patients. Metabolism
2011;60:1584–9.
10. Zhou D, Andersson TB, Grimm SW. In vitro evaluation of potential
drug-drug interactions with ticagrelor: cytochrome P450 reaction
phenotyping, inhibition, induction, and differential kinetics. Drug
Metab Dispos 2011;39:703–10.Key Words: atherosclerosis y chronic inflammation y coronary heart
disease y human immunodeficiency virus y immune activation.
